Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in New York City, NY, USA.
Poolbeg Pharma to attend HC Wainwright Global Investment Conference
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Amilia Stone
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms.
Poolbeg Pharma to showcase POLB 001's promising results in reducing CRS at ASH 2024, highlighting breakthroughs in cancer immunotherapy safety.
Discover six high-growth AIM-listed British companies delivering exceptional returns, with share prices surging up to 150% in the past year.
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF) has updated its registered address to 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.
